Servier exercises the exclusive worldwide license option of their collaboration program LRRK2

CTA approval by the ANSM and the EC of the phase 1 program resulting from the collaboration between Servier and OPM for the development of an innovative treatment in Parkinson's disease...

Oncodesign announces its results for the first half of 2022

28% growth in Service turnover

Oncodesign continues to grow in the first half of 2022

[Congress] Meet Oncodesign in person this spring

Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.